Healthcare · Profile from Healthcare Research Companion
Theranos, Inc.
The Palo Alto blood-testing startup that claimed it could run hundreds of laboratory tests from a few drops of blood from a fingertip, quickly and at a fraction of normal prices. It raised roughly $900m+ from private investors, reached a ~$9bn valuation in 2014, put testing centres in ~40 Walgreens stores, and then collapsed after the Wall Street Journal showed in October 2015 that its technology did not work as claimed. Regulators sanctioned it in 2016, the SEC charged its leaders with "massive fraud" in 2018, the company dissolved that year, and in 2022 founder Elizabeth Holmes and former president Ramesh "Sunny" Balwani were convicted of fraud. It is healthcare's defining story of evidence ignored.
At a glance
- Founded
- 2003, Palo Alto, California, as Real-Time Cures; renamed Theranos ("therapy" + "diagnosis")
- Founder
- Elizabeth Holmes (CEO), who left Stanford as a 19-year-old sophomore; Ramesh "Sunny" Balwani joined in 2009 as president and COO
- Headquarters
- Palo Alto, California; labs in Palo Alto and Newark (California) and Scottsdale (Arizona)
- Ownership / structure
- Private company; Holmes held ~50% of the equity and majority voting control (reported); dissolved September 2018
- Leadership
- Holmes (CEO 2003–June 2018); Balwani (president/COO 2009–May 2016); David Taylor (general counsel, then CEO for the wind-down, 2018)
- Segment and buyer
- Diagnostics and lab testing; intended buyers were consumers and physicians (via retail partners Walgreens and Safeway), payers (Capital BlueCross deal, 2015, reported), hospitals and the military
- Scale
- Peak ~800 employees (reported); tests performed for ~176,000 Arizona customers alone (Arizona AG, 2017); revenue never material and never disclosed publicly
- Capital raised / valuation
- ~$700m+ raised from late 2013 to 2015 alone (SEC); ~$900m+ over its life (reported, verify); ~$9bn post-money valuation (2014); Holmes's paper net worth ~$4.5bn (Forbes, 2014), revised to zero (2016)
- Signature moves (incl. failures)
- Founding and the "drop of blood" pitch (2003); Safeway partnership that never launched (signed ~2010, stalled by 2013, formally ended November 2015); Walgreens wellness centres (2013); ~$9bn valuation and celebrity board (2014); WSJ exposé and FDA inspection (2015); CMS sanctions and voided results (2016); SEC fraud charges and dissolution (2018); Holmes and Balwani convictions (2022)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2003
Founding and Drop of Blood Pitch
Founding
2010
Safeway Partnership Never Launched
Partnership (failure)
2013
Walgreens Wellness Centers Launch
Partnership / launch (failure)
2014
Nine Billion Valuation and Celebrity Board
Funding round / governance
2015
WSJ Expose and FDA Inspection
Crisis / regulatory scrutiny
2016
CMS Sanctions and Voided Results
Regulatory action / wind-down of lab operations
2018
SEC Fraud Charges and Dissolution
Regulatory settlement / criminal indictment / shutdown
2022
Holmes and Balwani Convictions
Criminal trial / sentencing